Episcleral Venous Pressure and the Ocular Hypotensive Effects of Topical and Intracameral Prostaglandin Analogs. by Lee, Susan S et al.
UC San Diego
UC San Diego Previously Published Works
Title
Episcleral Venous Pressure and the Ocular Hypotensive Effects of Topical and 
Intracameral Prostaglandin Analogs.
Permalink
https://escholarship.org/uc/item/1n82c9b7
Journal
Journal of glaucoma, 28(9)
ISSN
1057-0829
Authors
Lee, Susan S
Robinson, Michael R
Weinreb, Robert N
Publication Date
2019-09-01
DOI
10.1097/ijg.0000000000001307
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Episcleral Venous Pressure and the Ocular Hypotensive
Effects of Topical and Intracameral Prostaglandin Analogs
Susan S. Lee, PhD,* Michael R. Robinson, MD,*
and Robert N. Weinreb, MD†
Abstract: There is a limit beyond which increasing either the con-
centration of a prostaglandin analog (PGA) or its dosing frequency
fails to produce increases in ocular hypotensive efficacy with topical
dosing. Intracameral PGA dosing with a bimatoprost implant,
however, does not exhibit the same intraocular pressure (IOP)-
lowering plateau at studied concentrations, and the maximum-
achievable ocular hypotensive effects are not yet known. This
suggests that the bimatoprost intracameral implant may activate
another mechanism of action in addition to the mechanism(s)
activated by topical application. Episcleral venous pressure (EVP) is
a key determinant of IOP, and experimental manipulation of the
episcleral vasculature can change both EVP and IOP. The recent
observation that topical and intracameral PGA drug delivery routes
produce different patterns of conjunctival hyperemia suggested that
the differences in the IOP-lowering profiles may be caused by
differing effects on the episcleral vasculature. Recent experiments
in animals have shown that topical PGAs increase EVP, while
the bimatoprost intracameral implant causes a smaller, transient
increase in EVP, followed by a sustained decrease. The increase in
EVP could be limiting the IOP-lowering efficacy of topical PGAs.
In contrast, the decrease in EVP associated with the bimatoprost
implant could explain its enhanced IOP-lowering effects. Further
research on EVP as a target for IOP lowering is indicated to
improve our understanding of this potentially important pathway
for treating patients with glaucoma.
Key Words: bimatoprost, sustained release, intracameral, episcleral
venous pressure, intraocular pressure
(J Glaucoma 2019;28:846–857)
P rostaglandin analogs (PGAs) are the most widely usedfirst-line agents for lowering intraocular pressure (IOP) in
the treatment of glaucoma.1 It is well known, however, that
increasing the concentration of a topical PGA or the frequency
of topical PGA dosing beyond a certain point does not provide
additional IOP-lowering efficacy, and may even decrease
efficacy.2–4 It has recently been reported that the IOP lowering
produced by a bimatoprost intracameral implant (Bimatoprost
SR, Allergan plc), currently under development for the treat-
ment of glaucoma, has not shown a plateau at tested concen-
trations with increasing bimatoprost concentration.5 Moreover,
it exceeds the maximum IOP lowering achievable with topical
bimatoprost dosing. This suggests that the intracameral deliv-
ery of bimatoprost may activate another mechanism of action
in addition to what is activated by topical application. The
observation that topical and intracameral PGAs also produce
different patterns of conjunctival hyperemia led to the
hypothesis that the difference in IOP response to these 2 routes
of PGA delivery may be caused by their having different effects
on the episcleral vasculature and, therefore, episcleral venous
pressure (EVP).6 EVP is a key determinant of IOP,7 but its role
in the response to existing ocular hypotensive therapies is
unknown and, to date, it has been an elusive target for ther-
apeutic intervention.
This manuscript reviews the anatomy and physiology
of the episcleral vasculature, the relationship between EVP
and IOP, and the potential role of EVP in the ocular
hypotensive response to topical and intracameral PGAs.
THE EPISCLERAL VASCULATURE
The episcleral veins are the distal portion of the con-
ventional aqueous outflow pathway that begins at the tra-
becular meshwork (Fig. 1).8 Consequently, the pressure
gradient between the anterior chamber and the episcleral
veins has a significant effect on the rate of aqueous flow
through this pathway.7 Several distinctive characteristics of
the episcleral vasculature suggest that it is a highly regulated
vascular bed.8,9 These characteristics are conserved across
species (including rats, rabbits, dogs, owls, monkeys, and
humans), and this suggests that the episcleral vasculature
may have an important role in the control of normal
IOP.9–13
The episcleral vasculature is notable for a lack of capil-
laries, a muscle-rich venous network, and numerous arterio-
venous anastomoses (AVAs) that control the flow of blood
between arterioles and venules (Fig. 2).9 At the macroscopic
level, the episcleral vasculature can be distinguished from
conjunctival vessels by applying gentle lateral traction to the
conjunctiva; the conjunctival vessels will move with the con-
junctiva, while the episcleral vessels will not move.14 The
episcleral veins can be further identified by intracameral
injection of a fluorescent dye (eg, indocyanine green). When
this is done in beagle dogs, the episcleral veins can be dis-
tinguished from both conjunctival vessels and episcleralDOI: 10.1097/IJG.0000000000001307
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arterioles by their tendency to be longer and straighter than
other vessels (Fig. 3).6
The AVAs connecting the episcleral arterioles and
venules are characterized by a narrow (5 to 6 µm in dia-
meter) arteriolar segment and a wider (10 to 14 µm in dia-
meter) funnel-shaped venous segment (Fig. 2). There appear
to be between 4 and 10 AVAs per mm2 of the episcleral
venous plexus in the rat eye and between 20 and 30 AVAs
per mm2 in the rabbit eye.10 Although the role of the AVAs
in the eye is still being investigated, AVAs are known to
have an important role in other vascular beds. For example,
AVAs in the skin contribute to the regulation of body
temperature.15 They are nearly all closed when the temper-
ature is cool but open with increasing temperature or exer-
cise to direct blood to the surface where it can be cooled.15
In the lungs, AVAs seem to be generally constricted at rest
and to dilate during exercise, which may facilitate gas
exchange.16
Both episcleral arteries and veins are intensely innervated
by parasympathetic, sympathetic, and trigeminal nerve fibers.8
The vasoactive transmitters that have been found in nerve
terminals surrounding the episcleral vessels in monkeys and
humans include (but are not limited to) tyrosine hydroxylase,
neuropeptide Y, substance P, calcitonin gene-related peptide,
and vasoactive intestinal polypeptide.9 There is also evidence of
nitrergic innervation.9 In rabbits, application of the local
anesthetic proparacaine produces a rapid and marked decrease
in EVP, suggesting that the episcleral vasculature is under tonic
neural control in this species.17 In rats, electrical stimulation of
the superior salivatory nucleus (200 9-µA pulses, 1-ms duration,
20Hz) produced a significant increase in both EVP and IOP.18
In addition, several vasoactive substances have been shown to
FIGURE 1. The episcleral vasculature in relation to the other structures of the conventional outflow pathway. In this pathway, aqueous
flows through the trabecular meshwork, into Schlemm’s canal, and then through collector channels and aqueous veins that drain into the
episcleral veins.
FIGURE 2. Episcleral vasculature. A, Macroscopic view. B, Plastic cast, adapted from Funk and Rohen,12 published by Informa UK Limited.
Adaptations are themselves works protected by copyright. So in order to republish this adaptation, authorization must be obtained both
from the owner of the copyright in the original work and from the owner of copyright in the adaptation. Reprinted with permission of the
publisher Informa UK Limited trading as Taylor & Francis Ltd, www.tandfonline.com. Copyright Oxford University Press, Oxford, UK. All
permission requests for this image should be made to the copyright holders. Blue vessels are the episcleral venules; red vessels are the
episcleral arterioles; black and white arrows indicate arteriovenous anastomoses; blue arrows in (A) indicate collector channels (containing
a mix of aqueous and venous blood).
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have an effect on the episcleral vasculature and EVP. For
example, in rabbits, the nitric oxide donor nitroprusside causes
an increase in EVP and epinephrine produces a decrease in
EVP.11,19 In humans, the α2-adrenoceptor agonist clonidine
causes a decrease in EVP.20 The topical application of pilo-
carpine in humans causes an initial general vasodilation of
conjunctival and episcleral vessels, during which the episcleral
veins fill with blood and there is a transient increase in the
EVP.21
All of these characteristics suggest that the tone of the
episcleral vasculature (and therefore EVP) is both highly
regulated in normal eyes and potentially influenced by
exogenous substances in treated eyes.
RELATIONSHIP BETWEEN EPISCLERAL VESSEL
DIAMETER, EVP, AND IOP
The relationship between EVP and IOP is defined by
the modified Goldman equation as follows:
IOP¼EVPþ QUð ÞC:
In this equation, Q represents the aqueous inflow (in
µL/min), U represents the uveoscleral outflow (in µL/min),
and C represents conventional outflow facility through the
trabecular meshwork (µL/min/mmHg).7,22 Noninvasive
measurements of EVP in humans have varied widely among
investigators and laboratories, in large part because of the
subjective endpoints of vessel changes used for the
measurements.23 Many studies have reported mean EVP
values between 7 and 11 mmHg in normal subjects.23,24
Assuming a resting IOP of 15 to 17 mmHg and an EVP of 8
to 9mmHg, the modified Goldman equation suggests that
EVP accounts for ~47% to 60% of the IOP in humans.
Funk et al11 hypothesized that changes in EVP caused by
pharmacological manipulation of the episcleral vasculature,
particularly the diameter of the AVAs, could have a significant
impact on IOP. In a series of experiments in rabbits, they
demonstrated that changes in the diameter of the episcleral
outflow vessels (secondary to AVA opening and closing) can
affect the EVP and IOP. For example, AVA opening and a
shift of blood from the arteriole to the venule side, causing
vasodilation of the outflow vessels, increased the EVP and IOP.
Conversely, AVA closing, reducing blood flow from the arte-
riole to the venule side, caused vasoconstriction of the outflow
vessels and decreased the EVP and IOP (Fig. 4).
In these experiments, intraocular microendoscopy was
used for simultaneous in vivo observation of the episcleral
vascular bed and measurement of the episcleral vascular
pressure.11 This involved the use of a pressure chamber
attached to the tip of an endoscope. The pressure chamber was
filled with salt solution and connected to a hydrostatic reservoir
and a pressure transducer. Intravascular pressure was defined
as the pressure required to produce a 50% reduction in vessel
diameter. IOP was measured using an anterior chamber needle
connected to a pressure transducer. The mean resting pressure
(N=6 animals) was found to be 21.3±3.4mmHg in the
arterioles, 15.0±2.9mmHg in the AVAs, 12.6±2.7mmHg in
the venules, and 8.9±1.4mmHg in the veins of the episcleral
vasculature. The resting IOP was ~18mmHg. At rest, the
episcleral venules could be seen to contain a mix of blood and
FIGURE 3. Real-time fluorescent imaging was performed after
injection of indocyanine green (ICG) into the anterior chamber of
beagle dogs. Vessels running perpendicular to the limbus imme-
diately fluoresce following the ICG injection (arrows) suggesting
that these are the aqueous outflow vessels. Reprinted from Lee
et al6 with permission. Copyright the authors. All permission
requests for this image should be made to the copyright holder.
FIGURE 4. The effect of vasoactive agents on the episcleral vasculature, aqueous flow, EVP, and IOP in the rabbit.11 A, Normally, the
majority of AVAs are closed and the episcleral outflow vessels (venules) contain a mix of venous blood and aqueous humor. B, The
vasoconstrictor epinephrine causes the AVAs to collapse, and a reduction of blood flow from the arteriole (A) to the venule (V) side occurs,
leading to vasoconstriction and a decrease in both EVP and IOP. C, The vasodilator nitroprusside causes the AVAs to dilate. An increase of
blood flow from the arteriole to the venule side occurs, causing vasodilation and an increase in both EVP and IOP. AVA indicates
arteriovenous anastomosis; EVP, episcleral venous pressure; IOP, intraocular pressure.
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aqueous humor (indicating that the AVAs were at least parti-
ally open) (Fig. 4A).
The application of a topical vasoconstrictor (epi-
nephrine) caused all of the episcleral vessels to constrict, the
AVAs to close completely, and both EVP and IOP to
decrease11 (Fig. 4B). Some of the veins and venules were
observed to be completely filled with aqueous humor
because the collapse of the AVAs prevented any blood from
flowing in from the arterioles. The pressure decreased to
9.3 ± 2.9 mmHg in the AVAs (62% of initial value) and to
7.4 ± 1.6 mmHg in the episcleral veins (83% of initial value).
The IOP decreased from 18 to 13mmHg. In summary in
these animals, topical administration of epinephrine caused
complete constriction of the AVAs and closed off all blood
flow to the aqueous veins. Although some vasoconstriction
of the episcleral venules also occurred, a decrease in EVP,
believed to be because of the reduction in fluid volume in the
episcleral venules after closure of the AVAs, was observed
and resulted in a reduction in IOP.
In contrast, the application of a topical vasodilator
(nitroprusside) caused a dose-dependent dilation of the
episcleral vasculature, and an increase in both EVP and
IOP11 (Fig. 4C). There was marked hyperemia as veins and
venules, formerly perfused exclusively by aqueous humor,
filled with arterial blood flowing through the AVAs. The
blood impeded the outflow of aqueous humor and caused
IOP to increase from 18 to 21 mmHg. It also caused the
pressure in the episcleral AVAs, veins, and venules to
approach the pressure seen in the arterioles. The pressure
was 20.7 ± 1.4 mmHg in the AVAs (138% of initial value),
17.5 ± 3.4 mmHg in the venules (138% of initial value), and
15.5 ± 2.5 mmHg in the veins (123% of initial value).
A relationship between changes in EVP and IOP has also
been observed in humans. In a study of 11 healthy volunteers,
Friberg et al14 evaluated IOP and EVP in both supine and
inverted positions. In the supine position, mean IOP was
19.0±1.1mmHg and mean EVP was 7.9±0.63mmHg (42%
of IOP). Following inversion, mean IOP was 36.9±1.2mmHg
and mean EVP was 25.7±1.13mmHg (70% of IOP).
Regression analysis found that each 1mmHg increase in IOP
was associated with a 0.83±0.21mmHg increase in EVP.14
A similarly close relationship between changes in EVP and IOP
in healthy eyes was also observed by Blondeau et al.25 These
investigators measured EVP and IOP throughout a 24-hour
observation period in 12 healthy volunteers and found that
both pressures rose and fell in near parallel when the subjects
changed position. In the sitting position (4 PM), mean IOP
(measured with a Tonopen) was 15.6±3.56mmHg and mean
EVP was 8.1±1.26mmHg (52% of IOP). In the supine posi-
tion (6 AM), mean IOP was 17.3±2.24mmHg and mean EVP
was 10.5±1.33mmHg (61% of IOP).25
In the clinical setting, elevated EVP can be caused
by a variety of conditions such as arteriovenous shunts or
fistulas (Fig. 5A), Sturge-Weber syndrome, orbital tumors,
scleritis, thyroid-related orbitopathy, or large vessel venous
obstruction.26,28,29 Elevated EVP can also occur in the
absence of any apparent cause (idiopathic elevated
EVP).30,31 Patients with elevated EVP associated with these
conditions usually present with severe conjunctival hyper-
emia, high IOP, and open-angle glaucoma that is difficult to
treat.29–31 Several cases of severe conjunctival hyperemia
and elevated IOP associated with delayed hypersensitivity to
brimonidine (Fig. 5B) have also been described, and the
authors speculated that the increase in IOP in these patients
was caused by increased EVP.27
THE ROLE OF THE EPISCLERAL VASCULATURE IN
THE RESPONSE TO OCULAR HYPOTENSIVE PGAs
Topical ocular hypotensive PGAs have well-documented
vasoactive properties.32,33 They commonly produce ocular
surface vasodilation that manifests as mild and transient con-
junctival hyperemia—the most common adverse event asso-
ciated with topical PGA use in the treatment of glaucoma.2,4 In
the case of topical bimatoprost, this hyperemia has been found
to be caused by endothelial-derived nitric oxide-mediated vas-
odilation and is not associated with ocular surface
inflammation.33 Consequently, the hyperemia associated with
topical PGAs has generally been considered an esthetically
undesirable but clinically unimportant adverse event, unrelated
to clinical efficacy. The observation that topical and intra-
cameral PGAs have different IOP-lowering dose-response
profiles and produce different patterns of conjunctival hyper-
emia led to the hypothesis that the differing dose-response
profiles may be caused by differing effects on the episcleral
vasculature.
FIGURE 5. Examples of conditions associated with elevated episcleral venous pressure. A, Carotid-cavernous dural fistula.26 From Marx
and Nandakumar. Reproduced with permission from SLACK Incorporated. Copyright SLACK Incorporated, Thorofare, New Jersey. All
permission requests for this image should be made to the copyright holder. B, Delayed hypersensitivity to topical brimonidine.27
Reprinted with permission from Macmillan Publishers Ltd: Watts and Hawksworth. Copyright 2002 Nature Publishing Group, London,
UK. All permission requests for this image should be made to the copyright holder.
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Dose-Response: Topical PGAs
It has long been known that maximal IOP lowering with
topical PGAs is limited by an unknown mechanism and that
increasing either the drug concentration or dosing frequency
beyond a certain point does not increase IOP-lowering efficacy.
Early in the preclinical development of bimatoprost, for
example, it was noted that topical bimatoprost exhibited a
U-shaped dose-response curve in beagle dogs5 (Fig. 6A). The
IOP lowering increased from 16% to 36% with an increase in
bimatoprost concentration from 0.001% to 0.01%, but a further
increase in concentration to 0.1% resulted in a decrease in IOP-
lowering efficacy (Fig. 6A). In addition, in the phase 3 clinical
evaluation of bimatoprost 0.03% (300 µg/mL) in eyes with
glaucoma or ocular hypertension, the mean IOP reduction
from baseline (at 10 AM at month 6) was actually significantly
lower with twice-daily dosing (24.7%) than with once-daily
dosing (32.8%) (Fig. 6B).2 This has also been seen with lata-
noprost. Twice-daily dosing with latanoprost produces either
no additional benefit or a loss of IOP-lowering efficacy in
normal eyes4 as well as those with glaucoma34 or ocular
hypertension.35 Increasing the concentration of topical latano-
prost above 50 µg/mL is similarly ineffective. A 4-week, dose-
ranging study in eyes with primary open-angle glaucoma or
ocular hypertension found that IOP lowering was similar with
latanoprost concentrations ranging from 50 to 125 µg/mL.3
Dose-Response: Bimatoprost Intracameral Implant
The bimatoprost intracameral implant is a biodegradable,
sustained-release implant that is currently under development
for the treatment of glaucoma and ocular hypertension in
patients who are unsuitable for treatment with topical drops.36
Each implant contains preservative-free bimatoprost embedded
in a solid biodegradable polymer matrix. In preclinical studies,
the bimatoprost intracameral implant provided sustained
release of bimatoprost into the intracameral space for ~3 to
4 months, while the polymer matrix slowly biodegraded to
carbon dioxide and water. The implants that are continuing in
development contain 10 or 15 µg of bimatoprost, similar to the
amount of bimatoprost in 1 drop of topical bimatoprost 0.03%
solution (Lumigan, Allergan plc).36
In a preclinical dose-ranging study, the IOP-lowering
efficacy of dose strengths of bimatoprost intracameral
implant ranging from 8 to 120 µg was compared with that of
topical bimatoprost 0.03% in ocular normotensive beagle
dogs (n= 3 to 8 per dose group).5 The decrease from
baseline IOP increased with increasing bimatoprost intra-
cameral implant dose throughout the range tested (Fig. 7).
Eye examinations were performed at each visit by the vet-
erinary ophthalmologist, and uveitis was not present, sug-
gesting that ocular inflammation did not contribute to the
decrease in IOP. Moreover, the IOP lowering with bima-
toprost intracameral implant doses of 60 µg and above
exceeded that produced by topical bimatoprost 0.03%. In an
attempt to determine whether IOP lowering would plateau
at doses above 120 µg, a single animal was treated with a
bimatoprost implant providing a dose of 270 µg bimato-
prost. Surprisingly, IOP decreased even further with this
dose and, at this time, the maximum achievable IOP low-
ering with the bimatoprost intracameral implant in dogs is
not known.
A separate preclinical study was designed to see whether
the bimatoprost intracameral implant could decrease IOP when
added to a multidrug topical medication regimen that included
a PGA.37 In this study, 6 normotensive, chair-trained monkeys
FIGURE 6. Dose-response relationship for topical bimatoprost. A, Increasing concentration in beagle dogs. Error bars represent the
standard error of the mean. Reprinted from Lee et al5 under the terms of the CC BY license (https://creativecommons.org/licenses/by/4.0/).
B, Increasing dose frequency in a clinical study. Data reported by Sherwood and Brandt.2 IOP indicates intraocular pressure.
FIGURE 7. Mean percentage change in intraocular pressure (IOP)
from baseline in beagle dogs in the treated eye over 3 months after
administration of intracameral bimatoprost implant or a placebo
implant. Error bars indicate standard error of the mean. Dotted line
indicates the peak IOP reduction produced by 3 days of topical
bimatoprost 0.03% treatment (n=42). Asterisk indicates sentinel
dog data. Reprinted from Lee et al5 under the terms of the CC BY
license (https://creativecommons.org/licenses/by/4.0/).
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were treated with the topical fixed combination dorzolamide
2%/timolol 0.5% (Cosopt, Merck) bid plus topical latanoprost
0.005% qd for 5 weeks. At 5 weeks, the PGA was switched
from latanoprost 0.005% to bimatoprost 0.03%. At 8 weeks, 3
eyes in 3 animals were treated with bimatoprost intracameral
implant 20 µg. As can be seen in Figure 8, the addition of a
bimatoprost intracameral implant produced an additional 2 to
4mmHg of IOP lowering beyond what was achievable with
topical therapy alone.
A dose-response was also observed in the 6-month, phase
1/2 clinical trial of the bimatoprost intracameral implant in
patients with open-angle glaucoma.36 This study enrolled a total
of 75 patients who, in the investigator’s opinion, could be
treated adequately with topical bimatoprost 0.03% mono-
therapy. Each patient received a single treatment with a 6, 10,
15, or 20-µg bimatoprost intracameral implant in the study eye
(n=15 to 21 per group), and was instructed to apply topical
bimatoprost 0.03% once daily in the fellow eye. Decreases in
FIGURE 8. Effect of bimatoprost intracameral implant and topical ocular hypotensive therapy on mean IOP at peak effect in normo-
tensive monkeys. Topical therapy consisted of dorzolamide 2%/timolol 0.5% bid plus either latanoprost qd in the evening (weeks 0 to 5)
or bimatoprost qd in the evening (weeks 5 to 12). Peak effect was 2 hours after the morning topical dosing. Bimatoprost SR indicates
bimatoprost intracameral implant; IOP, intraocular pressure. Reprinted from Lee et al37 under the terms of the CC BY license (https://
creativecommons.org/licenses/by/4.0/).
FIGURE 9. Mean change from baseline IOP (8 AM time point) in study eyes of glaucoma patients after bimatoprost intracameral implant
administration and in fellow eyes treated with once-daily topical bimatoprost 0.03% (bim). Error bars represent standard error of the
mean. Bimatoprost SR indicates bimatoprost sustained-release implant; IOP, intraocular pressure. Adapted from Lewis et al36 with
permission. Adaptations are themselves works protected by copyright. So in order to publish this adaptation, authorization must be
obtained both from the owner of the copyright in the original work and from the owner of copyright in the adaptation.
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IOP in the study eye were observed as early as the day after
implant treatment and persisted through month 6. A dose-
response to the bimatoprost intracameral implant was generally
apparent during the first 12 weeks of the study (Fig. 9), and the
overall mean IOP reductions through week 16 in the study eye
were 7.2, 7.4, 8.1, and 9.5mmHg with the 6, 10, 15, and 20-µg
dose implants, respectively. This was similar to the mean overall
decrease of 8.4mmHg seen in the fellow eyes treated with
topical bimatoprost.36
Ocular PGAs and Hyperemia
The most common ocular adverse event associated
with topical PGAs is conjunctival hyperemia that is mostly
mild and transient.2–4,34,35 This hyperemia seems to be due
exclusively to vasodilation, as no evidence of inflammation
has been documented. In the case of bimatoprost, multiple-
dose, long-term (up to 1 y) safety studies were conducted in
rabbits, dogs, and nonhuman primates to specifically look
for signs of ocular surface inflammation, and none were
found.33 What was found, however, was that the hyperemia
produced by topically applied latanoprost or bimatoprost in
dogs could be inhibited by L-NAME (a nitric oxide synthase
inhibitor), suggesting that it is caused by vasodilation
mediated by endothelial cell-derived nitric oxide.33 There
does not appear to be an increase in the incidence of
hyperemia with an increase from once-daily to twice-daily
dosing,2,4 but there may be an increase in hyperemia with an
increase in PGA concentration.3,38
Studies then were conducted to determine whether
intracameral delivery of a PGA would reduce the risk of
FIGURE 10. Hyperemia in dog eyes after administration of (A)
topical bimatoprost and (B) bimatoprost intracameral implant.
FIGURE 11. Hypothetical effect of ocular hypotensive prosta-
glandin analogs on episcleral vasculature. A, Untreated. B, Gen-
eralized vasodilation after topical dosing. C, Selective vasodilation
of episcleral veins after intracameral dosing with the bimatoprost
intracameral implant (arrows indicate the route of bimatoprost
after intracameral dosing).
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conjunctival hyperemia, and this turned out to be the case in
humans. After a transient increase in erythema because of
the injection procedure itself, the incidence of hyperemia in
eyes treated with the bimatoprost intracameral implant falls
to less than half that seen in fellow eyes treated with topical
bimatoprost.36 What was also noted, however, in animal
studies where photographic assessment of the hyperemia
was performed, is that the pattern of hyperemia associated
with the 2 drug delivery methods was distinctly different
(Fig. 10). The hyperemia seen in eyes treated with topical
bimatoprost is characterized by general vasodilation of all
types of conjunctival and episcleral blood vessels (Fig. 10A).
The hyperemia associated with the bimatoprost intra-
cameral implant, however, seems to be largely caused by
FIGURE 12. A, Eye Tech episcleral venomanometer used to evaluate episceral venous pressure in beagle dogs. It is similar in design to a
Goldmann tonometer and mounts on a slit-lamp biomicroscope. B, The flexible transparent membrane on the tip of the venom-
anometer. It is dome shaped (arrow) and made of silicone rubber. Reprinted from Tsai et al,13 publisher John Wiley and Sons, Inc., with
permission. Copyright 2012 American College of Veterinary Ophthalmologists, Meridian, Idaho. All permission requests for this image
should be made to the copyright holder.
FIGURE 13. View through the episcleral venomanometer. A, The episcleral vein (black arrow) is identified and located within the aiming
ring on the silicone venomanometer tip. B, The pressure is increased until the vessel (black arrow) is 50% blanched. Reprinted from Tsai
et al,13 publisher John Wiley and Sons Inc., with permission. Copyright 2012 American College of Veterinary Ophthalmologists, Meridian,
Idaho. All permission requests for this image should be made to the copyright holder.
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vasodilation of long, straight episcleral vessels (Fig. 10B).
The episcleral vessels are deeper than the conjunctival ves-
sels and are nonmobile when the overlying conjunctiva is
manipulated with a cotton-tipped applicator.6 In a repre-
sentative dog injected intracamerally with indocyanine
green, fluorescence imaging of dye that moved from the
aqueous humor to outflow vessels verified that the long,
straight episcleral vessels running perpendicular to the lim-
bus and at least 4 mm posteriorly, and separated by ~1 clock
hour, were the aqueous outflow vessels.6 Thus, the vessels
dilated by the intracameral implant have characteristics of
episcleral aqueous outflow vessels (Fig. 10B). This suggests
that topical and intracameral bimatoprost have different
effects on the episcleral vasculature and, perhaps, on EVP.
Hypothesis: The Different Dose-Response Profiles
of Topical and Intracameral PGAs are Caused By
Differing Effects on the Episcleral Vasculature
If topical and intracameral PGAs have different effects on
the episcleral vasculature and EVP, then this could have an
effect on IOP-lowering efficacy that may manifest as differing
dose-response profiles. It was therefore hypothesized that high
doses or bid application of topical PGAs lead to dilation of all
conjunctival and episcleral vessels and their associated AVAs.6
This allows shunting of blood from the arterial (≈14 to
16mmHg) to the venous vessels (≈8 to 10mmHg), causing an
increase in EVP, and creating a barrier to further IOP lowering.
It was also hypothesized that intracameral dosing with
increasing doses of the bimatoprost implant leads to progressive
dilation of the episcleral veins only, because the episcleral
arterioles and AVAs are not exposed to drug when it is deliv-
ered intracamerally.6 This is illustrated in Figure 11. The
dilation of the episcleral veins leads to a decrease in EVP,
potentially helping to reduce IOP and to reduce the ability of
EVP to act as a barrier to further IOP lowering. If this
hypothesis is correct, then EVP measured during topical and
intracameral PGA dosing should be significantly different.
Evidence in support of this hypothesis was observed in
a series of experiments in normotensive beagle dogs.6,13 The
effect of topical latanoprost 0.005% qd on EVP was eval-
uated in 14 normotensive beagle dogs.13 In this study, EVP
was measured noninvasively using an episcleral venom-
anometer (Eyetech Ltd, Boca Raton, FL) (Fig. 12) with the
animals under general anesthesia. This episcleral venom-
anometer is similar to a Goldmann tonometer and mounts
on a slit-lamp biomicroscope. This device was chosen
because it is noninvasive and allows for serial measurements
from the same eye. The clinical appearance of episcleral
aqueous outflow vessels had been identified as those vessels
running perpendicular to the limbus (Fig. 3). To measure
EVP, the tip of the silicone membrane of the venom-
anometer was placed over an episcleral vein (~3 mm from
the limbus) and the pressure was slowly increased by turning
the venomanometer knob until the vessel was 50% blanched
(Fig. 13). Each reading was repeated in triplicate and the
median value recorded. Because it can take up to 5 days of
daily dosing with latanoprost to achieve maximal IOP
lowering, animals were dosed for 6 days before the first on-
treatment EVP measurement. Each animal was treated with
latanoprost 0.005% qd in 1 eye only, and the fellow, non-
dosed eye served as the control. Mean EVP in nondosed
eyes remained between 8.76 and 9.85 mmHg throughout the
study. In treated eyes, mean EVP was found to be sig-
nificantly higher than in nondosed fellow eyes at every
measurement during the dosing period (P< 0.0001; Fig. 14).
The greatest increase in EVP occurred after 13 days of
dosing: mean EVP was 15.01 mmHg in treated eyes and
9.85 mmHg in untreated fellow eyes.13
The effect of the bimatoprost intracameral implant on
EVP was evaluated in a separate study.6 In this study, EVP
was measured in normotensive beagle dogs that were
randomized to receive either bimatoprost intracameral
implant 30 µg (n= 7) or a sham injection (n= 7) in 1 eye. In
addition, IOP was measured in a separate group of animals
that had been trained for conscious IOP measurements and
were treated with bimatoprost intracameral implant 30 µg
(n= 8). The method of EVP measurement was the same as
used in the series of experiments with topical latanoprost.13
FIGURE 14. Mean episcleral venous pressure (± SD) for beagle
dogs treated with topical 0.005% latanoprost on study days 9 to
29. Reprinted from Tsai et al,13 publisher John Wiley and
Sons, Inc., with permission. Copyright 2012 American College of
Veterinary Ophthalmologists, Meridian, Idaho. All permission
requests for this image should be made to the copyright holder.
FIGURE 15. Mean EVP in eyes treated with bimatoprost intra-
cameral implant or sham injection. Error bars represent the
standard error of the mean. Bimatoprost SR indicates bimatoprost
intracameral implant. EVP indicates episcleral venous pressure.
*P<0.05 versus sham. Reprinted from Lee et al6 with permission.
Copyright the authors. All permission requests for this image
should be made to the copyright holder.
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In contrast to the response to topical latanoprost, eyes
treated with the bimatoprost intracameral implant exhibited
a transient increase in EVP that peaked at day 8
(+2.3 mmHg), followed by a gradual decrease to below
baseline (−2.4 to −3.9 mmHg) that was sustained through
day 65 (Fig. 15). There was no significant change in EVP in
the sham-treated eyes. In addition, eyes treated with the
bimatoprost intracameral implant exhibited a sustained
dilation of aqueous outflow vessels that was not seen in
sham-treated eyes (Fig. 16).6
The results of these experiments might not be gen-
eralizable to all species, where significant differences in
anatomy and baseline EVP measurements could potentially
influence the results. In addition, use of the “50% blanched”
endpoint in these dog studies may possibly have over-
estimated the true EVP. Nonetheless, the results suggest that
EVP may play an important but different role in the ocular
hypotensive effects of both topical and intracameral PGAs.
DISCUSSION
The observation that the IOP-lowering dose-response
for topical and intracameral bimatoprost is distinctly dif-
ferent suggests that intracameral delivery unlocks an addi-
tional mechanism of IOP lowering that is not accessible with
topical delivery. Subtle differences in the nature of the
hyperemia seen with the 2 routes of drug delivery6 indicated
that the episcleral vasculature was responding differently to
topical and intracameral bimatoprost and suggested that the
changes in EVP might also be different. Because EVP is so
important in the determination of IOP,7,22 it was hypothe-
sized that different effects on EVP could be the cause of the
different IOP-lowering profiles.
A tight linkage between EVP and IOP has been dem-
onstrated in several experiments in animals and
humans11,14,25 and is a natural consequence of the fact that
the episcleral veins comprise the distal portion of aqueous
outflow through the conventional pathway.8 It is not known
what contribution, if any, is made by EVP to the normal
control of IOP, but several characteristics of the episcleral
vasculature suggest that it is a highly regulated vascular bed
that serves an important physiological function. For
example, anatomic studies have revealed a muscle-rich
venous network that is intensely innervated by vasodilative
and vasoconstrictive nerves, and is connected to the epis-
cleral arterioles by numerous AVAs.8–10 It is also known
that the episcleral vasculature and EVP are sensitive to
several exogenously applied vasoactive substances.11,19–21 In
a series of elegant experiments in rabbits, Funk et al11
demonstrated that pharmacologically induced vasodilation
and vasoconstriction of the episcleral vasculature affect the
flow of blood through the AVAs, which, in turn, affects
EVP, the flow of aqueous into the episcleral veins, and IOP.
Overall vasodilation (produced by nitroprusside) caused the
AVAs to dilate, arterial blood to fill the venules, EVP to
increase, the outflow of aqueous to decrease, and IOP to
rise. Conversely, overall vasoconstriction (produced by
epinephrine) caused the AVAs to collapse, the flow of
arterial blood into the venules to cease, EVP to decrease, the
outflow of aqueous to increase, and IOP to fall.11
Topical ocular hypotensive PGAs are known to pro-
duce vasodilation of the ocular surface vasculature,32,33 so it
is reasonable to expect that they may increase EVP. What is
not immediately obvious, however, is how topical and
intracameral delivery of the same class of drugs could have
differing effects on EVP. The experiments of Funk et al11
suggest that general vasodilation of the episcleral vascula-
ture should cause an increase in both EVP and IOP. For an
intracamerally delivered PGA such as bimatoprost to cause
a decrease in EVP, it would have to produce selective vas-
odilation of the episcleral veins only, without opening the
AVAs. Observations of the nature of the hyperemia asso-
ciated with the bimatoprost intracameral implant in dogs
suggested that this may indeed be the case; this hyperemia
seems to be primarily caused by a selective vasodilation of
the episcleral veins. This insight inspired a recent series of
experiments to evaluate the effects of topical and intra-
cameral PGAs on EVP in beagle dogs.6,13
These experiments in beagle dogs showed that topical
and intracameral PGAs do have opposite effects on EVP
that could explain their differing IOP-lowering profiles.
Specifically, daily use of topical latanoprost caused a steady
increase in EVP,13 whereas the bimatoprost intracameral
implant caused a smaller, transient increase in EVP,
FIGURE 16. Surface blood vessels in beagle dogs 72 days after (A) bimatoprost intracameral implant insertion or (B) sham injection.
Reprinted from Lee et al6 with permission. Copyright the authors. All permission requests for this image should be made to the copyright
holder.
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followed by a sustained decrease.6 The increase in EVP
associated with topical application could be limiting the
IOP-lowering efficacy of topical PGAs, whereas the
decrease in EVP associated with the bimatoprost intra-
cameral implant could explain its expanded range of IOP
lowering. There may be other mechanisms involved as well.
Differing drug levels achieved with the different routes of
administration could potentially contribute to the differing
IOP-lowering profiles of the intracameral implant and top-
ical administration. In a study in dogs, maximal aqueous
humor drug levels were ~7-fold higher after administration
of the intracameral bimatoprost implant compared with
topical bimatoprost administration.39 Nonetheless, the EVP
experiments suggest that at least part of the difference in the
dose-response curves for topical and intracameral PGAs
may be because of opposing effects on EVP.
In conclusion, although EVP is an important determi-
nant of IOP, it has been an elusive target for therapeutic
intervention in glaucoma and ocular hypertension, perhaps
because of the complexity of the anatomy and physiology of
the episcleral vasculature. By lowering EVP, the bimato-
prost intracameral implant appears to unlock a new mech-
anism of PGA-mediated IOP lowering that is not accessible
with topical application. Further research on EVP as a
target for IOP lowering is indicated to improve our under-
standing of this potentially important pathway for treating
patients with glaucoma.
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